SOURCE: Viveve Medical, Inc.

Viveve Medical, Inc. Logo

April 22, 2015 08:28 ET

Viveve Announces Distribution Partnership With Neo Asia PTE, Ltd

Viveve Expands Commercialization to 4 New Countries in Asia Pacific

SUNNYVALE, CA--(Marketwired - April 22, 2015) - Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced the expansion of its commercial efforts into Singapore, Malaysia, Vietnam and Brunei in partnership with NeoAsia PTE, Ltd. ("NeoAsia"), a distributor of medical devices based in Singapore. The partnership combines NeoAsia's expertise in introducing new technologies and providing exceptional service with Viveve's innovative product for treating vaginal laxity.

"We're thrilled to be working with NeoAsia to bring the globally patented Viveve System, which provides a safe, painless treatment for vaginal laxity, to Singapore, Malaysia, Vietnam and Brunei. We believe that the treatment for the medical condition of vaginal laxity remains ineffectively addressed for millions of women worldwide. Now women in these countries, who have this very common and frustrating condition, will have access to a procedure that is aimed at reducing vaginal laxity and restoring sexual satisfaction. Having a strong partner like NeoAsia to introduce the procedure will help to ensure that physicians receive the best possible training and support as they begin offering the treatment," said Patricia Scheller, the Chief Executive Officer of Viveve.

NeoAsia focuses its distribution efforts on innovative products with solid scientific evidence, recognizing the need for clinicians to maintain high-quality standards and provide specialized solutions and positive results for their patients. The company prides itself on setting high standards for the products it represents and the service it provides its customers.

"NeoAsia is committed to seeking and distributing products that are clinically proven to be safe, effective and of the highest quality. We offer only what we believe are the finest technologies with evidence of ensuring safety and optimal results, all through science," said Jimmy Ang, MD, CEO and Managing Director of NeoAsia. "The Viveve System fits perfectly into our product portfolio and we're excited to offer this unique treatment to women throughout our territory."

About Viveve
Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.

Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc.

Contact Information

  • Contact:
    Amato and Partners, LLC
    Investor Relations Counsel
    90 Park Avenue. 17th Floor
    New York, NY 10016
    212.430.0360
    admin@amatoandpartners.com